Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the company. The HELIOS-B study met the primary endpoint, showing a statistically significant reduction, compared with placebo, in the composite of all-cause mortality and recurrent cardiovascular events …
Read More
